neoHIP: neoadjuvant HER2-targeted therapy +/- IO with pembrolizumab

Dual HER2-Targeted Neoadjuvant Therapy for BCПодробнее

HER2-E pCR with anti-HER2-based neoadjuvant therapiesПодробнее

Neoadjuvant treatment approach for HER2 positive breast cancerПодробнее

KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast CancerПодробнее

HER2+ Early-Stage Breast Cancer: Neoadjuvant StrategiesПодробнее

Neoadjuvant Approaches for Early-Stage HER2+ Breast CancersПодробнее

Neoadjuvant Therapy for HER2+ Breast CancerПодробнее

Neoadjuvant Treatment Strategies for HER2-Positive Breast CancerПодробнее

HER2+/ER- Breast Cancer: Neoadjuvant Therapy OptionsПодробнее

Pembrolizumab as adjuvant therapy for TNBCПодробнее

Case 1: Adjuvant Therapy for Residual Disease in HER2+ Breast CancerПодробнее

Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancerПодробнее

Neoadjuvant T-DM1 in Early-Stage HER2+ Breast CancerПодробнее

Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast CancerПодробнее

Multidisciplinary Assessment of HER2+ Breast CancerПодробнее

Consideration for Neoadjuvant Treatment in HER2+ Invasive Ductal CarcinomaПодробнее

HER2 Heterogeneity and Neoadjuvant Therapy in Breast CancerПодробнее

Utilizing neoadjuvant immunotherapies in patients with ER+, HER2- primary breast cancerПодробнее

The challenges of treating early-stage TNBCПодробнее